System L is an amino acid transport system that transports neutral amino acids, including several essential amino acids, in an Na ϩ -independent manner. 1) System L plays a major role in providing essential branched and aromatic amino acids in living cells. Due to its broad substrate selectivity, system L is proposed to mediate not only the transport of naturally occurring amino acids but also amino acid-related drugs, such as melphalan, an anticancer drug, L-dopa, a therapeutic drug for Parkinsonism, and gabapentin, an anticonvulsant.
ϩ -independent manner. 1) System L plays a major role in providing essential branched and aromatic amino acids in living cells. Due to its broad substrate selectivity, system L is proposed to mediate not only the transport of naturally occurring amino acids but also amino acid-related drugs, such as melphalan, an anticancer drug, L-dopa, a therapeutic drug for Parkinsonism, and gabapentin, an anticonvulsant. [1] [2] [3] LType amino acid transporter 1 (LAT1/SLC7a5) 4) and LAT2 (SLC7a8) 5) have been shown to encode as system L. These transporters are unique because they require an additional protein, the heavy chain of the 4F2 cell surface antigen (CD98/SLC3a2), for functional expression. The expression of LAT1 is localized at the blood-tissue barriers, such as brain capillary endothelial cells, syncytiotrophoblast cells, and retinal endothelial cells, while LAT2 is expressed ubiquitously. [6] [7] [8] Therefore, LAT1 plays a key role in transporting amino acid-related drugs to the brain and retina from the circulating blood.
L-Dopa is the most widely used drug for Parkinson's disease, since L-dopa and its metabolite, 3-O-methyldopa, are able to be transported via LAT1 in the luminal and abluminal membranes of the blood-brain barrier. 3) Melphalan has been thought to be mediated by system L because it is a phenylalanine derivative: phenylalanine-mustard.
2) However, Uchino et al. reported that melphalan is not transported rapidly compared with L-dopa and gabapentin because melphalan did not induce the efflux of [ 14 C]phenylalanine (Phe) preloaded on to oocytes expressing LAT1 through the obligatory exchange mechanism.
9) A number of alkylating agents, such as nitrogen-mustard, cyclophosphamide, and melphalan, but mostly melphalan, are used as cancer chemotherapy in patients with retinoblastoma. Melphalan is directly injected into the vitreous humor because it is not well transported from blood to the vitreous/retina through the blood-retinal barrier (BRB).
10) Consequently, it is important to understand the substrate recognition of amino acid-mustards for LAT1 as far as development of a transportable alkylating agent for LAT1 at the inner BRB is concerned.
The purpose of present study was to test the substrate recognition of synthetic amino acid-mustards: tyrosine-mustard, phenylglycine-mustard, alanine-mustard, ornithine-mustard, and lysine-mustard. In the present study, we have used a conditionally immortalized rat retinal endothelial cell line (TR-iBRB2), which expresses LAT1, 8) to examine LAT1-mediated transport of [ Synthesis of Amino Acid-Mustards Tyrosine-mustard, 11) phenylglycine-mustard, 12) ornithine-mustard, 13) and lysine-mustard 14) were prepared according to the literature procedures, and alanine-mustard was prepared from commercially available Boc-Dap-OtBu by the same procedure as that used for ornithine-mustard (Fig. 1) .
MATERIALS AND METHODS

Reagents
13) The structures were confirmed from the 1 H-NMR spectra (500 MHz, Cell Culture TR-iBRB2 cells possess endothelial markers and L-type amino acid transporter 1 (SLC7a5/LAT1), facilitative glucose transporter 1 (SLC2a1/GLUT1), P-glycoprotein (ABCB1a/mdr1a), creatine transporter (SLC6a8/ CRT), taurine transporter (SLC6a6/TauT), and scavenger receptor class B, type1 (SR-BI) which are expressed at the 8, [15] [16] [17] [18] Thus, TR-iBRB2 cells maintain certain in vivo functions and are a suitable in vitro model for the inner BRB. DMEM containing 100 U/ml benzylpenicillin potassium, 100 mg/ml streptomycin sulfate, and 10% FBS was used as the culture medium for TR-iBRB2 cells. TRiBRB2 cells (passage number 27-35) were seeded onto rat tail collagen type I-coated tissue culture plates (BD Biosciences, Franklin Lakes, NJ, U.S.A.) and cultured at 33°C in a humidified atmosphere of 5% CO 2 /air. The permissive-temperature for TR-iBRB2 cell culture is 33°C due to the presence of temperature-sensitive SV 40 large T-antigen. -free ECF buffers were prepared in two different ways: the choline ECF buffer was prepared by equimolar replacement of NaCl and NaHCO 3 with choline chloride and choline bicarbonate, respectively, while the Li ECF buffer was prepared by equimolar replacement of NaCl and NaHCO 3 with LiCl and KHCO 3 , respectively. Cl Ϫ -free ECF buffer was prepared by replacement with equimolar gluconate. After a predetermined period, uptake was terminated by removing the solution, followed by immersing cells in ice-cold uptake buffer to stop uptake. The cells were then solubilized in 1 N NaOH and subsequently neutralized with 1 N HCl. Cell-associated radioactivity and protein content were assayed by liquid scintillation spectrometry and detergent compatible protein assay (a DC protein assay kit, Bio-Rad, Hercules, CA, U.S.A.) with bovine serum albumin as a standard.
In For kinetic studies, the Michaelis-Menten constant (K m ), the maximal uptake rate (V max ) and nonsaturable uptake rate (K d ) of Phe uptake were calculated from the following equation (Eq. 3) using the nonlinear least-square regression analysis program, MULTI. 19 )
where V and S are the uptake rate of Phe for 1 min and the concentration of Phe, respectively. Unless otherwise indicated, all data represent meansϮ S.E.M. Statistical significance of differences among means of several groups was determined by one-way analysis of variance (ANOVA) followed by modified Fisher's least squares difference method. H]Phe uptake was inhibited by 2 mM L-phenylalanine, L-leucine, and 2-aminobicyclo-(2,2,1)-heptane-2-carboylic acid (BCH) by more than 85%. However, it was only inhibited by less than 30% in the presence of a substrate of LAT2, such as L-alanine, and the basic amino acid, L-arginine, at a concentration of 2 mM. These results support the evidence that [ Fig. 1 H]Phe uptake in the presence of 100 mM melphalan, tyrosine-mustard, and phenylglycine-mustard showed competitive inhibition with an inhibition constant (K i ) of 101 mM, 132 mM, and 231 mM, respectively (Fig. 3) . The amino acid-mustards that inhibited LAT1-medaited [ 3 H]Phe uptake were investigated to determine whether they could induce the efflux of loaded [ 3 H]Phe when applied extracellularly. As shown in Fig. 4 , the efflux of loaded [ 3 H]Phe was induced by 100 mM phenylglycine-mustard as well as LAT1 substrates, such as 2 mM phenylalanine, L-leucine, and BCH. No significant efflux was induced by melphalan, tyrosine-mustard, lysine-mustard, ornithine-mustard, and alaninemustard nor an LAT1-nonsubstrate, L-arginine.
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The present study demonstrates transport screening of synthetic amino acid-mustards and melphalan in TR-iBRB2 cells which express LAT1. Phenylglycine-mustard is a potent 2128 Vol. 31, No. 11 77.2Ϯ4.6** 100 mM melphalan 42.6Ϯ3.7* 100 mM tyrosine-mustard 48.6Ϯ1.6* 100 mM phenylglycine-mustard 52.3Ϯ3.6* 100 mM alanine-mustard 95.1Ϯ5.9 100 mM ornithine-mustard 86.1Ϯ7.1 100 mM lysine-mustard 58.9Ϯ3.6* [substrate for LAT1, better than melphalan, tyrosin-mustard, and aliphatic amino acid-mustards. System L transports neutral amino acids in an Na ϩ -independent manner and is classified as LAT1 and 2. Recently, LAT3 (SLC43a1) 20) and 4 (SLC43a2) 21) have been identified as a lower affinity transporter for system L. LAT1 and 2 offer higher affinity for Phe transport (Ͻ100 mM) than that of LAT3 and 4 (Ͼ1 mM). 4, 5, 20, 21) [ 3 H]Phe uptake by TR-iBRB2 cells was Na ϩ -independent and saturable with a K m of 86.8 mM (Fig. 2) . This uptake had only a minor effect in the presence of 2 mM L-alanine (Table 1) . 4, 5) These results are very consistent with LAT1-mediated [
3 H]Phe uptake by TR-iBRB2 cells. Uchino et al., investigated the mechanism of substrate recognition for LAT1 and found that LAT1 accepts a-methyl amino acids as substrates. 9) In order to recognize amino acid derivatives that are substrates for LAT1, they most probably needed to have positive and negative charges at the a-carbon and hydrophobic moiety.
9) Therefore, we selected a-amino acids which have an aromatic moiety, or b-hydroxyl, d-and e-amino groups. Aromatic amino acids introduce a mustard moiety to an aromatic ring: tyrosine-mustard and phenylglycine-mustard. The b-hydroxyl group of L-serine is substituted by a mustard moiety, alanine-mustard, and the d-and eamino group of L-ornithine and L-lysine are substituted by a mustard moiety, ornithine-mustard and lysine-mustard, respectively (Fig. 1) .
Aliphatic amino acid-mustards, such as alanine-mustard and ornithine-mustard, failed to inhibit [ 3 H]Phe uptake by TR-iBRB2 cells, suggesting that these compounds do not interact with LAT1 (Table 1) . Lysine-mustard and aromatic amino acid-mustards inhibited [ 3 H]Phe uptake by TR-iBRB2 cells by more than 40%, suggesting that the amino acid with hydrophobic moiety provides higher affinity binding site for LAT1. LAT1 is an amino acid exchange transporter which makes it possible to evaluate whether compounds accepted by the binding site of LAT1 are transported or not by examining their ability to induce the efflux of loaded radiolabeled substrate. 8, 9) This strategy is particularly useful for compounds with no readily available radiolabeled form. Of the aromatic amino acid-mustards, although melphalan has the highest binding affinity for LAT1 (Fig. 3) , melphalan failed to induce the efflux of loaded [ 3 H]Phe as is in the case of Larginine which is not a substrate for LAT1 (Fig. 4) . In addition to melphalan, tyrosine-mustard, alanine-mustard, ornithine-mustard, and lysine-mustard did not induce any significant efflux, suggesting that these compounds are faint substrates of LAT1. In contrast, phenylglycine-mustard induced the efflux of loaded [ 3 H]Phe as is the case with transportable substrates of LAT1, such as L-phenylalanine, Lleucine, and BCH. This suggests that phenylglycine-mustard is a better substrate for LAT1 than other amino acid-mustards. Although further studies are needed to determine the anti-tumor activities for phenylglycine-mustard, phenylglycine-mustard is a more potent substrate of LAT1 than melphalan, tyrosine-mustard, and lysine-mustard.
Based on the results of the present study, we propose a model for a transportable alkylating agent for LAT1. An aromatic amino acid as a backbone is produced with greater affinity for LAT1 than an aliphatic amino acid since the aromatic moiety is more hydrophobic than the aliphatic moiety. Of the aromatic amino acid-mustards, the glycine moiety of phenylglycine-mustard is one carbon shorter than the alanine moiety of melphalan and tyrosine-mustard. Phenylglycinemustard may adapt to the binding site of LAT1 as a transportable form because introduction of the mustard moiety may be sufficiently marked to interrupt the transport of phenylalanine and tyrosine. LAT1 is expressed not only at the inner BRB 8) but also in malignant tumors. 22) These pieces of evidence suggest that phenylglycine-mustard is transported from the circulating blood to the retina across the inner BRB. Subsequently, phenylglycine-mustard may be taken up by retinoblastoma.
In conclusion, the data presented here show that phenylglycine-mustard is a potent substrate of LAT1 more than melphalan, tyrosine-mustard, and aliphatic amino acid-mustards. These findings provide important information to increase our understanding of the substrate binding and transport mechanisms of LAT1 and help in the development of a transportable alkylating agent for LAT1. 
